LT2970272T - Glikozidazės inhibitoriai - Google Patents
Glikozidazės inhibitoriaiInfo
- Publication number
- LT2970272T LT2970272T LTEP14724185.5T LT14724185T LT2970272T LT 2970272 T LT2970272 T LT 2970272T LT 14724185 T LT14724185 T LT 14724185T LT 2970272 T LT2970272 T LT 2970272T
- Authority
- LT
- Lithuania
- Prior art keywords
- glycosidase inhibitors
- glycosidase
- inhibitors
- Prior art date
Links
- 239000003316 glycosidase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361782353P | 2013-03-14 | 2013-03-14 | |
| US201361817493P | 2013-04-30 | 2013-04-30 | |
| PCT/US2014/022630 WO2014159234A1 (en) | 2013-03-14 | 2014-03-10 | Glycosidase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2970272T true LT2970272T (lt) | 2019-04-25 |
Family
ID=50729762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP14724185.5T LT2970272T (lt) | 2013-03-14 | 2014-03-10 | Glikozidazės inhibitoriai |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9879001B2 (lt) |
| EP (1) | EP2970272B1 (lt) |
| JP (1) | JP6360147B2 (lt) |
| CN (1) | CN105143222B (lt) |
| AU (1) | AU2014241065B2 (lt) |
| CA (1) | CA2899088C (lt) |
| DK (1) | DK2970272T3 (lt) |
| ES (1) | ES2723883T3 (lt) |
| HR (1) | HRP20190857T1 (lt) |
| HU (1) | HUE043398T2 (lt) |
| IL (1) | IL241512B (lt) |
| LT (1) | LT2970272T (lt) |
| PL (1) | PL2970272T3 (lt) |
| PT (1) | PT2970272T (lt) |
| RS (1) | RS58768B1 (lt) |
| SI (1) | SI2970272T1 (lt) |
| WO (1) | WO2014159234A1 (lt) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3868752A1 (en) * | 2014-08-28 | 2021-08-25 | Asceneuron SA | Glycosidase inhibitors |
| EP3389658B1 (en) * | 2015-12-18 | 2020-11-25 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
| WO2017139975A1 (en) * | 2016-02-19 | 2017-08-24 | Huiru Wang | Antibodies against n-acetylglucosamine and n-acetyl-galactosamine |
| US10344021B2 (en) | 2016-02-25 | 2019-07-09 | Asceneuron S A | Process for the separation of enantiomers of piperazine derivatives |
| SG11201807012QA (en) | 2016-02-25 | 2018-09-27 | Asceneuron S A | Acid addition salts of piperazine derivatives |
| WO2018153508A2 (en) * | 2017-02-24 | 2018-08-30 | Asceneuron S.A. | Sulfoximine glycosidase inhibitors |
| AU2017222958B2 (en) * | 2016-02-25 | 2019-07-18 | Asceneuron S. A. | Glycosidase inhibitors |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| CN108884078A (zh) * | 2016-02-25 | 2018-11-23 | 阿森纽荣股份公司 | 糖苷酶抑制剂 |
| EP3555087A1 (en) * | 2016-12-16 | 2019-10-23 | Janssen Pharmaceutica NV | Monocyclic oga inhibitor compounds |
| US20190359609A1 (en) * | 2016-12-16 | 2019-11-28 | Janssen Pharmaceutica Nv | Bicyclic oga inhibitor compounds |
| TWI654978B (zh) * | 2017-01-27 | 2019-04-01 | 美商美國禮來大藥廠 | 5－甲基－1,2,4－二唑－3－基化合物 |
| WO2018154133A1 (en) | 2017-02-27 | 2018-08-30 | Janssen Pharmaceutica Nv | [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors |
| AR111693A1 (es) | 2017-05-25 | 2019-08-07 | Lilly Co Eli | Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga |
| WO2019037860A1 (en) * | 2017-08-24 | 2019-02-28 | Asceneuron S.A. | LINEAR INHIBITORS OF GLYCOSIDASE |
| US11459324B2 (en) | 2018-03-14 | 2022-10-04 | Biogen Ma Inc. | O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors |
| JP7453916B2 (ja) * | 2018-03-14 | 2024-03-21 | バイオジェン・エムエイ・インコーポレイテッド | Ｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グリコピラノシダーゼ阻害剤 |
| TWI726329B (zh) | 2018-06-22 | 2021-05-01 | 美商美國禮來大藥廠 | 2,3-二氫呋喃并[2,3-b]吡啶化合物 |
| CA3107788A1 (en) | 2018-07-31 | 2020-02-06 | Eli Lilly And Company | Combination of anti-tau antibody and oga inhibitor for treatment of diseases characterized by aberrant tau aggregation |
| US11999726B2 (en) | 2018-07-31 | 2024-06-04 | Eli Lilly And Company | 5-methyl-4-fluoro-thiazol-2-yl compounds |
| WO2020039027A1 (en) * | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Pyrrolidine glycosidase inhibitors |
| WO2020039029A1 (en) * | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Spiro compounds as glycosidase inhibitors |
| WO2020039028A1 (en) * | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Tetrahydro-benzoazepine glycosidase inhibitors |
| IL280841B2 (en) | 2018-08-22 | 2024-12-01 | Asceneuron S A | Succinate and fumarate acid addition salts of piperazine derivatives useful as glycosidase inhibitors |
| US12180205B2 (en) * | 2018-09-19 | 2024-12-31 | Biogen Ma Inc. | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |
| TWI716107B (zh) | 2018-09-26 | 2021-01-11 | 美商美國禮來大藥廠 | 6-氟-2-甲基苯并[d]噻唑-5-基化合物 |
| ES2968733T3 (es) * | 2018-12-05 | 2024-05-13 | Biogen Ma Inc | Derivados morfolinilo, piperazinilo, oxazepanilo y diazepanilo útiles como inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa |
| JP7663503B2 (ja) * | 2019-03-08 | 2025-04-16 | バイオジェン・エムエイ・インコーポレイテッド | アゼチジニルｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤 |
| AR120324A1 (es) * | 2019-10-29 | 2022-02-09 | Biogen Ma Inc | Inhibidores de o-glucoproteína-2-acetamido-2-deoxi-3-d-glucopiranosidasa espirocíclica |
| WO2021094312A1 (en) | 2019-11-11 | 2021-05-20 | Janssen Pharmaceutica Nv | Pyrrolidine and bicycloheteroaryl containing oga inhibitor compounds |
| WO2021110656A1 (en) | 2019-12-02 | 2021-06-10 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
| WO2021123291A1 (en) | 2019-12-18 | 2021-06-24 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
| US20230058733A1 (en) | 2019-12-18 | 2023-02-23 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
| CN114867725A (zh) | 2019-12-18 | 2022-08-05 | 詹森药业有限公司 | Oga抑制剂化合物 |
| KR102533471B1 (ko) * | 2020-11-23 | 2023-05-19 | (주) 메디프론디비티 | O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도 |
| CN112480018B (zh) * | 2020-11-30 | 2023-06-20 | 中国药科大学 | 一种trpv3小分子变构抑制剂及其制备方法 |
| PE20241304A1 (es) * | 2021-07-30 | 2024-06-24 | Confo Therapeutics N V | Compuestos para el tratamiento del dolor, en particular el dolor neuropatico, y/u otras enfermedades o trastornos que se asocian con at2r y/o senalizacion mediada por at2r |
| AU2022371475A1 (en) | 2021-10-22 | 2024-05-09 | Eli Lilly And Company | O-glcnacase (oga) inhibitor combination therapy |
| WO2024047185A1 (en) * | 2022-08-31 | 2024-03-07 | Janssen Pharmaceutica Nv | Mass spectroscopy assay for detecting o-beta-linked n-acetylglucosaminylated tau peptides |
| WO2026021588A1 (zh) * | 2024-07-26 | 2026-01-29 | 浙江同源康医药股份有限公司 | Oga抑制剂及其应用 |
| US12612396B1 (en) | 2024-11-20 | 2026-04-28 | Dewpoint Therapeutics, Inc. | Modulators of beta catenin and uses thereof |
| CN120884613B (zh) * | 2025-10-09 | 2026-02-17 | 浙江省人民医院 | 一种基于嗜黏蛋白阿克曼氏菌的抑制肿瘤制剂 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2533923A1 (fr) * | 1982-10-05 | 1984-04-06 | Cortial | Nouvelles n-(aminomethyl-5 oxazolin-2 yl-2) n'-phenylurees, leur methode de preparation ainsi que leur application therapeutique |
| US4600025A (en) | 1982-11-18 | 1986-07-15 | Grigg Ronald E | Smoking products comprising nicotine substitutes |
| RU2340605C2 (ru) * | 2002-06-27 | 2008-12-10 | Ново Нордиск А/С | Арилкарбонильные производные в качестве терапевтических средств |
| AU2003243921B2 (en) | 2002-06-27 | 2009-05-07 | Novo Nordisk A/S | Aryl carbonyl derivatives as therapeutic agents |
| JP2006504796A (ja) * | 2002-10-09 | 2006-02-09 | ファイザー・プロダクツ・インク | 神経変性性障害を処置するためのチアゾール化合物 |
| BRPI0506662B8 (pt) * | 2004-01-06 | 2021-05-25 | Novo Nordisk As | compostos ativadores de glucoquinase |
| JP2009500377A (ja) | 2005-07-08 | 2009-01-08 | ノボ・ノルデイスク・エー／エス | ジシクロアルキルウレア型グルコキナーゼ活性化剤 |
| EP2057171A4 (en) | 2006-08-31 | 2010-04-21 | Univ Fraser Simon | SELECTIVE GLYCOSIDASE INHIBITORS AND APPLICATIONS THEREOF |
| US8148369B2 (en) | 2007-05-10 | 2012-04-03 | Janssen Pharmaceutica Nv | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2009086303A2 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US7863291B2 (en) | 2008-04-23 | 2011-01-04 | Bristol-Myers Squibb Company | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| AU2010221417A1 (en) * | 2009-03-02 | 2011-09-22 | Sirtris Pharmaceuticals, Inc. | 8-substituted quinolines and related analogs as sirtuin modulators |
| WO2010108115A1 (en) | 2009-03-20 | 2010-09-23 | Sanford-Burnham Medical Research Institute | Allosteric jnk inhibitors |
| JP2010270034A (ja) | 2009-05-20 | 2010-12-02 | Sumitomo Chemical Co Ltd | アミド化合物並びにその植物病害防除用途 |
| CN103435606A (zh) | 2013-08-22 | 2013-12-11 | 中国药科大学 | CDK2与GSK3β双重抑制剂及用途 |
-
2014
- 2014-03-10 PT PT14724185T patent/PT2970272T/pt unknown
- 2014-03-10 CN CN201480014258.5A patent/CN105143222B/zh active Active
- 2014-03-10 HR HRP20190857TT patent/HRP20190857T1/hr unknown
- 2014-03-10 US US14/775,134 patent/US9879001B2/en active Active
- 2014-03-10 EP EP14724185.5A patent/EP2970272B1/en active Active
- 2014-03-10 CA CA2899088A patent/CA2899088C/en active Active
- 2014-03-10 PL PL14724185T patent/PL2970272T3/pl unknown
- 2014-03-10 WO PCT/US2014/022630 patent/WO2014159234A1/en not_active Ceased
- 2014-03-10 ES ES14724185T patent/ES2723883T3/es active Active
- 2014-03-10 AU AU2014241065A patent/AU2014241065B2/en active Active
- 2014-03-10 DK DK14724185.5T patent/DK2970272T3/en active
- 2014-03-10 HU HUE14724185A patent/HUE043398T2/hu unknown
- 2014-03-10 SI SI201431216T patent/SI2970272T1/sl unknown
- 2014-03-10 RS RS20190638A patent/RS58768B1/sr unknown
- 2014-03-10 LT LTEP14724185.5T patent/LT2970272T/lt unknown
- 2014-03-10 JP JP2016501020A patent/JP6360147B2/ja active Active
-
2015
- 2015-09-10 IL IL241512A patent/IL241512B/en active IP Right Grant
-
2017
- 2017-12-04 US US15/830,675 patent/US10301299B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2899088A1 (en) | 2014-10-02 |
| CA2899088C (en) | 2022-12-20 |
| US20160031871A1 (en) | 2016-02-04 |
| JP2016517411A (ja) | 2016-06-16 |
| SI2970272T1 (sl) | 2019-06-28 |
| WO2014159234A1 (en) | 2014-10-02 |
| DK2970272T3 (en) | 2019-04-23 |
| ES2723883T3 (es) | 2019-09-03 |
| IL241512A0 (en) | 2015-11-30 |
| AU2014241065A1 (en) | 2015-08-13 |
| PT2970272T (pt) | 2019-06-05 |
| IL241512B (en) | 2020-08-31 |
| PL2970272T3 (pl) | 2019-09-30 |
| US20180093977A1 (en) | 2018-04-05 |
| HUE043398T2 (hu) | 2019-08-28 |
| US10301299B2 (en) | 2019-05-28 |
| AU2014241065B2 (en) | 2017-08-31 |
| CN105143222A (zh) | 2015-12-09 |
| JP6360147B2 (ja) | 2018-07-18 |
| EP2970272A1 (en) | 2016-01-20 |
| CN105143222B (zh) | 2018-02-02 |
| RS58768B1 (sr) | 2019-06-28 |
| EP2970272B1 (en) | 2019-02-27 |
| US9879001B2 (en) | 2018-01-30 |
| HRP20190857T1 (hr) | 2019-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT2970272T (lt) | Glikozidazės inhibitoriai | |
| EP2970340A4 (en) | BETA-Lactamase INHIBITORS | |
| IL245846B (en) | syk inhibitors | |
| EP2943204A4 (en) | BETA-Lactamase INHIBITORS | |
| IL243578A0 (en) | syk inhibitors | |
| IL240962A0 (en) | cdc7 inhibitors | |
| EP2948450A4 (en) | METALLOENZYMINHIBITORVERBINDUNGEN | |
| IL239827A0 (en) | Deoxyuridine triphosphatase inhibitors | |
| IL245442A0 (en) | gsk–3 inhibitors | |
| IL265496A (en) | bace1 inhibitors | |
| ZA201506156B (en) | Novel inhibitors | |
| IL245245A0 (en) | New dgat2 inhibitors | |
| GB201317609D0 (en) | Inhibitor compounds | |
| LT3063139T (lt) | Heterociklinis junginys | |
| GB201313664D0 (en) | Bcl-3 inhibitors | |
| GB201305503D0 (en) | Inhibitor | |
| GB201307155D0 (en) | Kinase inhibitors | |
| GB201321328D0 (en) | Inhibitor compounds | |
| GB201310577D0 (en) | Secnidazole |